Trial Profile

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azithromycin (Primary) ; Roflumilast (Primary)
Indications Chronic bronchitis; Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms RELIANCE

Most Recent Events

06 Jun 2024 Phase changed from III to IV.
06 Jun 2024 Planned number of patients changed from 1200 to 1250.
06 Jun 2024 Planned End Date changed from 1 Feb 2027 to 1 May 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com